prognostic value of her2-low status in breast cancer: a systematic review and meta-analysis
Published 1 year ago • 208 plays • Length 2:30Download video MP4
Download video MP3
Similar videos
-
7:13
overview of the management of her2-low breast cancer patients
-
5:57
prognostic value of circulating tumour-cell count in metastatic breast cancer patients
-
0:49
dr. o’regan on prognostic value of pcr in her2 breast cancer
-
1:10
the evolution of her2-low-positive breast cancer as a clinical subtype
-
1:14
prognostic value of beta-2 adrenergic receptor levels in her2 breast cancer
-
0:45
the evolution of her2-low breast cancer from primary to recurrence
-
1:36
is her2-low a distinct subtype of breast cancer?
-
1:33
questions remaining in the field of her2-low breast cancer
-
1:17
clinical outcomes in women with metastatic her2-low breast cancer in the real world
-
30:27
advances in her2-positive and her2-low breast cancer
-
3:06
prognostic score in early hr /her2- breast cancer: rs, factors, mutations, histology
-
5:40
trastuzumab deruxtecan doubles pfs in metastatic breast cancer with low her2 expression
-
6:46
updates on her2-low breast cancer
-
3:31
her2-low mbc patients report preserved qol with trastuzumab deruxtecan
-
1:09
the exciting new field of her2-low breast cancer
-
1:45
the comprehensive genomic characterization of her2-low breast cancer
-
1:20:02
her2-low expression in breast cancer: opportunities for expanding treatment benefit to more patients
-
2:13
remaining questions surrounding her2-low breast cancer – how low can you go?
-
1:25:22
a new view of the spectrum of her2 expression and significance of her2 low in breast cancer